Novartis has reported positive topline results from two pivotal Phase 3 trials of remibrutinib in relapsing multiple sclerosis, saying the oral Bruton’s tyrosine kinase inhibitor significantly reduced annualized relapse rates compared with teriflunomide in both independently conducted studies. REMODEL-1 and REMODEL-2 also met all key secondary endpoints within each trial, including measures of inflammatory brain lesions, while a preplanned pooled analysis showed a positive trend in three-month confirmed disability progression and nominal statistical significance for six-month confirmed disability progression. The Swiss pharmaceutical company plans global regulatory submissions following presentation of the detailed data at MSToronto2026.
The announcement is potentially important because approximately 2,000 patients participated across the two trials, giving Novartis replicate Phase 3 evidence rather than relying on one successful pivotal study. However, the September 1 press release does not disclose the actual annualized relapse rates, percentage reductions, MRI-lesion counts or disability hazard ratios. Those numbers will be essential for judging whether remibrutinib is merely statistically superior to teriflunomide or clinically competitive with the increasingly high efficacy expected from modern multiple sclerosis therapies.
How did Novartis test remibrutinib in the REMODEL Phase 3 program?
REMODEL-1 and REMODEL-2 are identically designed, multicenter, randomized, double-blind Phase 3 trials comparing remibrutinib with teriflunomide in adults with relapsing multiple sclerosis. Roughly 2,000 patients with recent disease activity and Expanded Disability Status Scale scores between 0 and 5.5 were randomized 1:1 to remibrutinib 100 mg or teriflunomide, with the blinded core phase lasting as long as 30 months before an open-label extension of up to five years. The primary endpoint in both studies is annualized relapse rate, giving regulators two separate tests of whether the investigational medicine can consistently reduce clinical disease activity.
Key secondary endpoints extend well beyond relapses. Investigators are tracking three- and six-month confirmed disability progression, new or enlarging T2 brain lesions, gadolinium-enhancing T1 lesions, serum neurofilament light chain and the proportion of patients achieving no evidence of disease activity. Novartis says remibrutinib was superior to teriflunomide on all key secondary endpoints within each REMODEL trial, including MRI lesion reduction, making the forthcoming detailed presentation particularly important for determining the breadth of the treatment effect.
Why are BTK inhibitors being developed for multiple sclerosis?
Bruton’s tyrosine kinase plays a role in signaling within B cells and innate immune cells, both of which participate in the inflammatory processes associated with multiple sclerosis. Remibrutinib is designed to selectively inhibit BTK and potentially influence inflammatory activity without broadly depleting B cells, offering a different therapeutic approach from monoclonal antibodies that remove substantial portions of the B-cell population. Novartis believes this could create an oral therapy capable of combining meaningful efficacy with a treatment profile suitable for long-term use.
The attraction of BTK inhibition also extends into the central nervous system because researchers are interested in whether sufficiently active molecules can influence immune processes contributing to chronic neuroinflammation and disability progression. That ambition is harder to demonstrate than reducing acute relapses, which is why disability data will become increasingly important as the class matures. REMODEL’s pooled signal on six-month confirmed disability progression is encouraging, but the absence of the underlying numerical result means it remains impossible to judge the magnitude from the topline announcement alone.
Why does the absence of a liver safety signal matter?
Safety has become a closely watched issue for the broader BTK inhibitor field, making Novartis’ statement that no liver safety signal emerged especially relevant. Across REMODEL-1 and REMODEL-2, the company reported no cases meeting Hy’s Law criteria, a regulatory framework used to identify drug-induced liver injury with the potential to become severe. The overall safety findings were described as consistent with a remibrutinib development program that has exposed more than 4,500 participants across multiple indications.
Remibrutinib is not an entirely untested molecule commercially. A 25 mg formulation is already marketed as Rhapsido for chronic spontaneous urticaria following U.S. approval in September 2025 and European approval in April 2026. Multiple sclerosis, however, involves a different dose, disease biology, duration of treatment and competitive landscape, so experience in urticaria cannot substitute for evaluating the complete REMODEL safety dataset.
Could remibrutinib become a high-efficacy oral alternative in relapsing MS?
That is the commercial position Novartis is trying to establish. Multiple sclerosis treatment currently spans oral medicines, injectable therapies and highly effective monoclonal antibodies, leaving physicians to balance disease suppression against infection risk, monitoring burden, convenience and patient preference. A tablet that produces efficacy approaching higher-intensity therapies while maintaining a favorable safety profile could occupy an attractive position, particularly for patients unwilling to move immediately to infusion- or injection-based treatment.
The difficulty is that “high efficacy” ultimately needs numbers. Statistical superiority to teriflunomide establishes that remibrutinib works better than the active comparator used in REMODEL, but clinicians will want to examine absolute relapse rates, MRI outcomes, discontinuations and disability progression before comparing it with the broader MS treatment landscape. Novartis has deliberately held that detailed dataset for MSToronto2026, making the congress presentation the real clinical-value event following today’s positive topline announcement.
What happens next for Novartis and remibrutinib?
Novartis plans to seek regulatory approval for remibrutinib in relapsing multiple sclerosis globally after releasing the detailed Phase 3 results. Development is also continuing in secondary progressive multiple sclerosis through the REMASTER program, meaning the company is testing whether BTK inhibition can produce benefits beyond the more inflammatory relapsing population. Other remibrutinib programs include hidradenitis suppurativa and food allergy, adding to the already approved chronic spontaneous urticaria indication.
The most important immediate question is therefore not whether REMODEL succeeded, because Novartis has clearly said both pivotal studies met their primary endpoint. It is how large the advantage was and whether the disability and safety profiles make remibrutinib competitive enough to change prescribing behavior. Two successful Phase 3 trials give Novartis a strong regulatory starting point, but the withheld efficacy numbers will determine whether this becomes merely another MS approval candidate or one of the most consequential oral entrants into the market.
